Deltex Medical Group Plc从事先进血流动力学监测技术的研发和销售。公司总部位于西萨塞克斯郡奇切斯特,目前有37名全职员工。该公司开发、制造并分销血流动力学监测技术。其TrueVue平台提供三种监测技术,包括食道多普勒监测(ODM+)、脉压波形分析(PPWA)和高清晰度阻抗心电图(HD-ICG)。其ODM+是一种液体管理和心输出量监测技术,可直接测量成人和儿科患者的血流和压力。HD-ICG提供连续且灵敏的心输出量及其他血流动力学参数的测量。系统通过HD-Z信号滤波技术实现稳定。HD-ICG的一次性电极放置在颈部和胸部。PPWA使用经过研究的脉压波算法,通过多普勒校准来推导血流动力学参数。其应用领域包括外科手术、急性肾损伤、加速康复、儿科以及新冠肺炎重症监护。
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for DTXMF. Our analysts highlight strong fundamentals and favorable market sentiment, positioning DTXMF for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: DTXMF is a Strong Buy candidate.
DTXMF stock price ended at $0.1 on 星期三, after dropping NaN%
On the latest trading day Feb 05, 2025, the stock price of DTXMF fell by NaN%, dropping from $0.10 to $0.10. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.10 and a high of $0.10. On the latest trading day, the trading volume for DTXMF decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 302 shares were traded, with a market value of approximately $189.6M.